Mainz Biomed B.V. (MYNZ) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Diagnostics & Research 산업에서 운영. 본사 소재지는 Mainz, 독일. 현재 CEO는 Guido Baechler.
MYNZ 을(를) 보유 IPO 날짜 2021-11-05, 19 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $2.86M.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
